Wells Fargo & Company Issues Pessimistic Forecast for Integra LifeSciences (NASDAQ:IART) Stock Price

Integra LifeSciences (NASDAQ:IART) had its target price decreased by equities researchers at Wells Fargo & Company from $25.00 to $13.00 in a report issued on Tuesday,Benzinga reports. The firm presently has an “equal weight” rating on the life sciences company’s stock. Wells Fargo & Company‘s price objective suggests a potential upside of 2.12% from the company’s current price.

Other analysts also recently issued reports about the company. JPMorgan Chase & Co. reduced their price objective on Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating on the stock in a research report on Tuesday. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Finally, Truist Financial lowered their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating for the company in a report on Friday, April 11th. Four analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Hold” and an average price target of $19.88.

Integra LifeSciences Price Performance

Integra LifeSciences stock opened at $12.73 on Tuesday. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The firm’s 50-day simple moving average is $19.31 and its 200 day simple moving average is $21.96. Integra LifeSciences has a 52 week low of $11.60 and a 52 week high of $32.66. The firm has a market capitalization of $983.39 million, a PE ratio of -141.43, a P/E/G ratio of 0.73 and a beta of 1.27.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $382.65 million during the quarter, compared to analyst estimates of $381.17 million. During the same quarter in the prior year, the company earned $0.55 earnings per share. The firm’s revenue for the quarter was up 3.7% compared to the same quarter last year. On average, equities research analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Institutional investors have recently bought and sold shares of the stock. Quadrant Capital Group LLC raised its stake in Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 1,371 shares during the period. Sterling Capital Management LLC increased its holdings in shares of Integra LifeSciences by 821.7% during the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock worth $49,000 after buying an additional 1,931 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock worth $74,000 after buying an additional 2,800 shares during the period. Covestor Ltd boosted its holdings in Integra LifeSciences by 61.8% in the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company’s stock valued at $123,000 after acquiring an additional 2,071 shares during the last quarter. Finally, CWM LLC grew its position in Integra LifeSciences by 413.8% during the first quarter. CWM LLC now owns 6,664 shares of the life sciences company’s stock valued at $147,000 after acquiring an additional 5,367 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.